JP2023116479A5 - - Google Patents
Info
- Publication number
- JP2023116479A5 JP2023116479A5 JP2023083666A JP2023083666A JP2023116479A5 JP 2023116479 A5 JP2023116479 A5 JP 2023116479A5 JP 2023083666 A JP2023083666 A JP 2023083666A JP 2023083666 A JP2023083666 A JP 2023083666A JP 2023116479 A5 JP2023116479 A5 JP 2023116479A5
- Authority
- JP
- Japan
- Prior art keywords
- nlg3
- seq
- sequence
- set forth
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1620119.6 | 2016-11-29 | ||
| GBGB1620119.6A GB201620119D0 (en) | 2016-11-29 | 2016-11-29 | Compounds |
| JP2019548783A JP7683901B2 (ja) | 2016-11-29 | 2017-11-28 | 筋肉性能改善化合物 |
| PCT/IB2017/057436 WO2018100483A1 (en) | 2016-11-29 | 2017-11-28 | Muscle performance improvement compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548783A Division JP7683901B2 (ja) | 2016-11-29 | 2017-11-28 | 筋肉性能改善化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023116479A JP2023116479A (ja) | 2023-08-22 |
| JP2023116479A5 true JP2023116479A5 (https=) | 2025-10-08 |
Family
ID=58073474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548783A Active JP7683901B2 (ja) | 2016-11-29 | 2017-11-28 | 筋肉性能改善化合物 |
| JP2023083666A Pending JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548783A Active JP7683901B2 (ja) | 2016-11-29 | 2017-11-28 | 筋肉性能改善化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11407799B2 (https=) |
| EP (1) | EP3548509A1 (https=) |
| JP (2) | JP7683901B2 (https=) |
| KR (1) | KR102622245B1 (https=) |
| CN (1) | CN110036024B (https=) |
| AU (1) | AU2017367277B2 (https=) |
| CA (1) | CA3045245A1 (https=) |
| GB (1) | GB201620119D0 (https=) |
| NZ (1) | NZ754625A (https=) |
| WO (1) | WO2018100483A1 (https=) |
| ZA (1) | ZA201903261B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN115379850A (zh) * | 2019-12-24 | 2022-11-22 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| WO2021189010A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| WO2022019829A1 (en) * | 2020-07-24 | 2022-01-27 | Agency For Science, Technology And Research | Wound healing composition and uses thereof |
| WO2022192411A1 (en) * | 2021-03-10 | 2022-09-15 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| WO2022271466A1 (en) | 2021-06-21 | 2022-12-29 | Juvena Therapeutics, Inc. | Regenerative polypeptides and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503673A (ja) * | 1993-10-14 | 1997-04-15 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞の誘導および維持法 |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| WO2008021896A2 (en) | 2006-08-08 | 2008-02-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic methods for neuropathic pain |
| BRPI0716249A2 (pt) | 2006-09-05 | 2013-09-03 | Lilly Co Eli | anticorpos antimiostatina |
| EA018221B1 (ru) | 2007-02-09 | 2013-06-28 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| PE20120532A1 (es) * | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| EP2295068A1 (en) * | 2009-09-04 | 2011-03-16 | Neurotune AG | Modified agrin-fragment capable of restoring muscle strength for use as a medicament |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
-
2016
- 2016-11-29 GB GBGB1620119.6A patent/GB201620119D0/en not_active Ceased
-
2017
- 2017-11-28 NZ NZ754625A patent/NZ754625A/en unknown
- 2017-11-28 CN CN201780073720.2A patent/CN110036024B/zh active Active
- 2017-11-28 EP EP17808609.6A patent/EP3548509A1/en active Pending
- 2017-11-28 KR KR1020197018624A patent/KR102622245B1/ko active Active
- 2017-11-28 JP JP2019548783A patent/JP7683901B2/ja active Active
- 2017-11-28 WO PCT/IB2017/057436 patent/WO2018100483A1/en not_active Ceased
- 2017-11-28 CA CA3045245A patent/CA3045245A1/en active Pending
- 2017-11-28 US US16/464,969 patent/US11407799B2/en active Active
- 2017-11-28 AU AU2017367277A patent/AU2017367277B2/en active Active
-
2019
- 2019-05-23 ZA ZA2019/03261A patent/ZA201903261B/en unknown
-
2023
- 2023-05-22 JP JP2023083666A patent/JP2023116479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023116479A5 (https=) | ||
| NO20063026L (no) | Antistoffer | |
| JP2023540732A5 (https=) | ||
| JP2010521147A5 (https=) | ||
| JP2023082054A5 (https=) | ||
| DiCara et al. | Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin αvβ6: implications for infectiousness | |
| EP2135879A3 (en) | Ligand | |
| RU94045826A (ru) | Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i | |
| JP2024116321A5 (https=) | ||
| JP2002536960A5 (https=) | ||
| JP2007535490A5 (https=) | ||
| JP2016196472A5 (https=) | ||
| JP2020507561A5 (https=) | ||
| HRP20230761T1 (hr) | Gdf zamke | |
| JP2003527079A5 (https=) | ||
| ES2333598T5 (es) | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. | |
| JP2023537070A5 (https=) | ||
| JP2019506159A5 (https=) | ||
| MA29226B1 (fr) | Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| MX2022010203A (es) | Tratamiento inmune profilactico y terapeutico de propionibacterium acnes. | |
| JP2019535321A5 (https=) | ||
| JP2022513331A5 (https=) | ||
| JP2016535741A5 (https=) | ||
| DE60239467D1 (de) | Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin |